EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating ZIP14 Expression and Inducing Ferroptosis

Zhuoying Yang, Zehao Zhou, Qingyu Meng, Zhijie Chen, Liang Yun, Jianjun Jiang, Yujing He, Meijuan Dian, Ruihao Zhang, Haotian Ge, Tianbao Yan, Biying Men und 4 weitere

Cancer Medicine · 2024-10 · 13 (19)

DOI: 10.1002/cam4.70271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.10.2024. Verfasst von Zhuoying Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Artemisinins, Ferroptosis, Cisplatin, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University, the Central High-Level Hospital Clinical Research Special Project, Peking Union Medical College Hospital, the Guangdong Provincial Key Laboratory Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite significant advances in lung cancer treatment, cisplatin (DDP)‐based chemotherapy remains a cornerstone for managing the disease. However, the prevalence of chemoresistance presents a major challenge, limiting its effectiveness and contributing to poor outcomes. This underscores the urgent need for novel therapeutic strategies to overcome chemoresistance and improve chemotherapy efficacy in lung cancer patients. Exploring approaches to sensitize tumors to cisplatin could enhance treatment responses and overall survival rates. Methods and Results Our study utilized a variety of lung cancer models, including cell lines, mouse models, and patient‐derived organoids, to validate the synergistic cytotoxic effects of dihydroartemisinin (DHA) and cisplatin (DDP). When combined with DDP, we demonstrate that DHA is a promising therapeutic agent that effectively triggers ferroptosis in lung cancer cells, offering a potential strategy for overcoming chemoresistance. Mechanistically, the combination of DHA and DDP synergistically enhances ZIP14 expression, modulating iron homeostasis and upregulating oxidative stress, leading to both in vitro and in vivo ferroptosis. Notably, our findings revealed that the sequential administration of DDP followed by DHA significantly increases ZIP14 expression and induces superior therapeutic outcomes compared to the simultaneous administration or DHA followed by DDP. This observation underscores the importance of the drug administration order in optimizing treatment efficacy, providing new insights into enhancing chemotherapy response in lung cancer.

Conclusion

Our findings suggest that combining dihydroartemisinin (DHA) with cisplatin (DDP) presents a promising strategy to overcome chemoresistance in lung cancer patients. Importantly, administering DHA during chemotherapy intervals could further optimize treatment outcomes, enhancing the overall efficacy of lung cancer chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArtemisininsFerroptosisCisplatinLung NeoplasmsHumansMiceAnimalsDrug Resistance, NeoplasmCell Line, TumorDrug SynergismUp-RegulationXenograft Model Antitumor AssaysAntineoplastic Combined Chemotherapy ProtocolsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

ZIP14cisplatindihydroartemisininferroptosislung cancernon‐transferrin iron transport

Substanzen

ArtemisininsartenimolCisplatin

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

ORCID-Profile: Shuan Rao

Förderung

  • the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University
  • the Central High-Level Hospital Clinical Research Special Project, Peking Union Medical College Hospital
  • the Guangdong Provincial Key Laboratory Science and Technology Plan Project
  • the China Postdoctoral Science Foundation
  • the National Natural Science Foundation of China
  • the Program of Marine Economy Development Special Fund (Six Marine Industries) under Department of Natural Resources of Guangdong Province
  • the Guangdong Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Zhou, Z., Meng, Q., Chen, Z., Yun, L., Jiang, J., He, Y., Dian, M., Zhang, R., Ge, H., Yan, T., Men, B., Li, Z., Wu, X., He, J., & Rao, S. (2024). Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating ZIP14 Expression and Inducing Ferroptosis. Cancer Medicine, 13(19). https://doi.org/10.1002/cam4.70271

Vancouver

Yang Z, Zhou Z, Meng Q, Chen Z, Yun L, Jiang J, et al. Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating ZIP14 Expression and Inducing Ferroptosis. Cancer Medicine. 2024;13(19). doi:10.1002/cam4.70271

BibTeX
@article{Yang2024,
  author = {Yang, Zhuoying and Zhou, Zehao and Meng, Qingyu and Chen, Zhijie and Yun, Liang and Jiang, Jianjun and He, Yujing and Dian, Meijuan and Zhang, Ruihao and Ge, Haotian and Yan, Tianbao and Men, Biying and Li, Zichao and Wu, Xu and He, Junming and Rao, Shuan},
  title = {Dihydroartemisinin Sensitizes Lung Cancer Cells to Cisplatin Treatment by Upregulating ZIP14 Expression and Inducing Ferroptosis},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {19},
  doi = {10.1002/cam4.70271}
}
Kostenlos starten →